Medicenna Reports Breakthrough Trial Results and Extended Runway
Company Announcements

Medicenna Reports Breakthrough Trial Results and Extended Runway

Story Highlights

Medicenna Therapeutics Corp (TSE:MDNA) has released an update.

Medicenna Therapeutics Corp. announced promising clinical trial results for its immunotherapy drug MDNA11, showing significant tumor regression in melanoma and pancreatic cancer patients who were previously resistant to other treatments. The company has also secured a financial investment extending its operational runway to mid-2026 and plans to present further updates in the second half of 2024.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reports Promising Results with MDNA11
TipRanks Canadian Auto-Generated NewsdeskMedicenna Announces Breakthroughs in Cancer Treatment
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reveals Key Immunotherapy Data at SITC
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App